PRODUCTS
Pipeline
| PROGRAM | Fc DESIGN | PRIMARY INDICATION | DISCOVERY LEAD | PRE CLINICAL |
PHASE 1 | PHASE 2 | COMMERCIAL RIGHTS |
| XmAb® 5574 (MOR208) Anti-CD19 |
High ADCC | B-Cell Malignancies |  |
|
|
|
MorphoSys |
| XmAb® 5871 Anti-CD19/CD32b |
Immuno-modulatory | Autoimmune Diseases | |
|
|
Optioned (Amgen) | |
| XmAb® 2513 Anti-CD30 |
High ADCC | Hodgkin’s Lymphoma | |
|
|
Xencor | |
| PF-4605412 | High ADCC | Oncology | |
|
|
Pfizer | |
| Undisclosed | High ADCC | Oncology | |
|
|
Boehringer Ingelheim | |
| Undisclosed | High ADCC | Oncology | |
|
|
Boehringer Ingelheim | |
| Undisclosed | High ADCC | Oncology | |
|
|
CSL Ltd. | |
| XmAb® 7195 Anti-IgE/CD32b |
Immuno-modulatory | Asthma Allergy |
|
|
Xencor | ||
| XmAb® 5485 Anti-CD40 |
High ADCC | B-Cell Malignancies | |
|
Xencor | ||
| XmAb® 5592 Anti-HMI.24 |
High ADCC | Myeloma | |
|
Xencor |